Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases

View through CrossRef
Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase (100 mg/day per os) in patients admitted to vascular surgery. Patients were of both sexes, >18 years of age, with vascular diseases (i.e., deep vein thrombosis, superficial vein thrombosis, venous insufficiency), and naïve to specific pharmacological treatments (anticoagulants or anti-platelets). Patients were divided into three groups. Group 1: patients with deep vein thrombosis, treated with fondaparinux plus nattokinase. Group 2: patients with phlebitis, treated with enoxaparin plus nattokinase. Group 3: patients with venous insufficiency after classical surgery, treated with nattokinase one day later. During the study, we enrolled 153 patients (age 22–92 years), 92 females (60.1%) and 61 males (39.9%;), and documented that nattokinase was able to improve the clinical symptoms (p < 0.01) without the development of adverse drug reactions or drug interactions. Among the enrolled patients, during follow-up, we did not record new cases of vascular diseases. Attention to patients’ clinical evolution, monitoring of the INR, and timely and frequent adjustment of dosages represent the cornerstones of the safety of care for patients administered fibrinolytic drugs as a single treatment or in pharmacological combination. Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases.
Title: Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases
Description:
Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity.
Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery.
In this study, we evaluated both the efficacy and the safety of nattokinase (100 mg/day per os) in patients admitted to vascular surgery.
Patients were of both sexes, >18 years of age, with vascular diseases (i.
e.
, deep vein thrombosis, superficial vein thrombosis, venous insufficiency), and naïve to specific pharmacological treatments (anticoagulants or anti-platelets).
Patients were divided into three groups.
Group 1: patients with deep vein thrombosis, treated with fondaparinux plus nattokinase.
Group 2: patients with phlebitis, treated with enoxaparin plus nattokinase.
Group 3: patients with venous insufficiency after classical surgery, treated with nattokinase one day later.
During the study, we enrolled 153 patients (age 22–92 years), 92 females (60.
1%) and 61 males (39.
9%;), and documented that nattokinase was able to improve the clinical symptoms (p < 0.
01) without the development of adverse drug reactions or drug interactions.
Among the enrolled patients, during follow-up, we did not record new cases of vascular diseases.
Attention to patients’ clinical evolution, monitoring of the INR, and timely and frequent adjustment of dosages represent the cornerstones of the safety of care for patients administered fibrinolytic drugs as a single treatment or in pharmacological combination.
Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases.

Related Results

Biotechnology, Bioengineering and Applications of Bacillus Nattokinase
Biotechnology, Bioengineering and Applications of Bacillus Nattokinase
Thrombosis has threatened human health in past decades. Bacillus nattokinase is a potential low-cost thrombolytic drug without side-effects and has been introduced into the consume...
Biotechnology, Bioengineering and Applications of <em>Bacillus </em>Nattokinase
Biotechnology, Bioengineering and Applications of <em>Bacillus </em>Nattokinase
Thrombosis has threatened human health in past decades. Bacillus nattokinase is a potential thrombolytic drug without side-effect and low cost and has been introduced into the cons...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
In silico analysis of Nattokinase from Bacillus subtilis sp natto
In silico analysis of Nattokinase from Bacillus subtilis sp natto
Nattokinase or subtilisin NAT (EC 3.4.21.62) is one of the most remarkable enzymes produced by Bacillus subtilis sp.Natto, which posses direct fibrinolytic activity. The aim of thi...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash Abstract This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
PRODUCTION, OPTIMIZATION AND PARTIAL PURIFICATION OF NATTOKINASE FROM BACILLUS CEREUS; A STRAIN ISOLATED FROM GRAPE WINE
PRODUCTION, OPTIMIZATION AND PARTIAL PURIFICATION OF NATTOKINASE FROM BACILLUS CEREUS; A STRAIN ISOLATED FROM GRAPE WINE
In the current study a potent fibrinolytic protease producing Bacillus cereus VMI2 was isolated from Grape wine (Vitis vinifera) and studied the protease activity and fibrinolytic ...

Back to Top